STOCK TITAN

Cytosorbents Corp - CTSO STOCK NEWS

Welcome to our dedicated news page for Cytosorbents (Ticker: CTSO), a resource for investors and traders seeking the latest updates and insights on Cytosorbents.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cytosorbents's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cytosorbents's position in the market.

Rhea-AI Summary
CytoSorbents Corporation re-appoints Kathleen P. Bloch as full-time CFO, effective retroactively to September 2, 2023. Bloch's return provides continuity and stability to the company as it targets US and Canadian approval for DrugSorb®-ATR and capitalizes on improvements in the acute care markets and investments in CytoSorb® business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.04%
Tags
none
-
Rhea-AI Summary
CytoSorbents highlights the potential of ex vivo organ perfusion in organ transplantation and the role of CytoSorb® and ECOS-300CY® in improving outcomes. Recent studies show that CytoSorb and EVLP can reduce inflammation, improve lung function, and decrease the incidence of severe primary graft dysfunction (PGD) in lung transplantation. Human studies demonstrate that CytoSorb integrated with EVLP leads to lower in-hospital and one-year mortality rates and higher transplant success rates. These results have the potential to transform the field of organ transplantation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.07%
Tags
none
-
Rhea-AI Summary
CytoSorbents Corporation's Chief Financial Officer, Alexander D'Amico, has resigned as part of a mutual termination agreement, effective August 28, 2023. No severance payments or equity vesting will occur. Kathleen Bloch will continue as the Interim CFO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Summary
CytoSorb® granted expanded medical device registration in Brazil to treat shock, a common complication of critical illness and cardiac surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
none
-
Rhea-AI Summary
CytoSorbents Corporation has completed the pivotal STAR-T trial, evaluating the ability of DrugSorb-ATR to reduce perioperative bleeding in patients undergoing cardiothoracic surgery. Readout of topline results expected before year-end. The goal is to provide a reversal agent for the blood thinner Brilinta®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.7%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.46%
Tags
earnings
Rhea-AI Summary
CytoSorbents Corporation (NASDAQ: CTSO) to Report Second Quarter 2023 Operating and Financial Results on August 1st, 2023. The company will host a live presentation webcast and a question and answer session at 4:30PM EDT the same day. Participants can join the webcast or conference call for detailed insights into the company's performance and future prospects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.88%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
management
-
Rhea-AI Summary
CytoSorbents Corporation and Humedics GmbH have announced a collaboration in the field of liver disease. CytoSorbents' CytoSorb® blood purification technology is expanding the dimension of blood purification as the only EU approved extracorporeal liver support therapy. The collaboration aims to increase market awareness and sales of their respective technologies in the liver field.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.49%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
none
Cytosorbents Corp

Nasdaq:CTSO

CTSO Rankings

CTSO Stock Data

51.58M
46.68M
9.17%
39.53%
3.08%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Monmouth Junction

About CTSO

cytosorbents (nasdaq: ctso) cytosorbents corporation is a leader in critical care immunotherapy, specializing in blood purification. its flagship product, cytosorb® is approved in the european union with distribution in 40 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm"​ or "cytokine release syndrome"​ that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. these are conditions where the risk of death is extremely high, yet no effective treatments exist. cytosorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. cytosorbents'​ purification technologies are based on biocompatible, highly porous polymer beads